A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

NCT05710848 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle-invasive Bladder Cancer

Interventions

DRUG: STM-416

Sponsor

SURGE Therapeutics